ORG Wealth Partners’s Spyre Therapeutics SYRE Stock Holding History

ORG Wealth Partners’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$267	Buy	+3	New	+$288	﹤0.01%	2286

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

ORG Wealth Partners's SYRE Position: Q3 2026 in Review

ORG Wealth Partners opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 3 shares worth $267. The stake represents ﹤0.01% of the portfolio and ranks #2286 among its holdings.

165 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

ORG Wealth Partners held 3 shares of Spyre Therapeutics worth $267 as of Q3 2026.
Spyre Therapeutics was a new ORG Wealth Partners position in Q3 2026.
Spyre Therapeutics made up ﹤0.01% of ORG Wealth Partners's portfolio in Q3 2026, its #2286 holding.
165 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on ORG Wealth Partners's 13F filing for Q3 2026, filed 3 Nov 2026.